Analyzing Black Titan (NASDAQ:BTTC) & Intellicheck (NASDAQ:IDN)

Intellicheck (NASDAQ:IDN) and Black Titan (NASDAQ:BTTC) are both small-cap services companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Profitability

This table compares Intellicheck and Black Titan’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellicheck	9.56%	11.26%	8.92%
Black Titan	N/A	N/A	N/A

Valuation and Earnings

This table compares Intellicheck and Black Titan”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellicheck	$22.67 million	3.77	$1.27 million	$0.11	38.41
Black Titan	$180,000.00	45.71	-$4.71 million	($2.95)	-0.26

Intellicheck has higher revenue and earnings than Black Titan. Black Titan is trading at a lower price-to-earnings ratio than Intellicheck, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Intellicheck and Black Titan, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellicheck	0	2	3	1	2.83
Black Titan	1	0	0	0	1.00

Intellicheck currently has a consensus price target of $7.38, indicating a potential upside of 74.56%. Given Intellicheck’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Intellicheck is more favorable than Black Titan.

Insider & Institutional Ownership

42.8% of Intellicheck shares are held by institutional investors. 7.8% of Intellicheck shares are held by company insiders. Comparatively, 0.7% of Black Titan shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Intellicheck has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Black Titan has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Summary

Intellicheck beats Black Titan on 13 of the 15 factors compared between the two stocks.

About Intellicheck

Intellicheck, Inc., a technology company, develops, integrates, and markets threat identification and identity authentication solutions for bank and retail fraud prevention, law enforcement threat identification, and mobile and handheld access control and security systems primarily in the United States. It provides identity systems products, including commercial identification products, such as Intellicheck Platform, an identity solution that checks whether an ID is valid, matches the ID to the person presenting it, and provides a risk score to determine the risk of doing business with that person; IDN-Portal that provides the ability to scan an ID using a mobile phone; IDN-Portal+ that uses a retail scanner to validate an ID, and get additional data for analytics and analysis; IDN-Direct that provides access to additional data and the ability to use the platform’s Risk Score capability to help with decision-making; and Intellicheck mobile app, which provides the ability to login and scan an ID. The company also offers State Aware Software solution, which provides or restricts information that is electronically scanned from an ID based on the electronic reading laws according to the state in which the ID is scanned; data collection devices that enable its software applications to be used on a variety of commercially available credit card terminals, PDAs, tablets, laptops, desktops, mobile phones, and point-of-sale terminals; and instant credit application kiosk software applications. It serves government, military, and commercial markets. The company was formerly known as Intellicheck Mobilisa, Inc. and changed its name to Intellicheck, Inc. in May 2017. Intellicheck, Inc. was incorporated in 1994 and is headquartered in Melville, New York.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.